Anodyne Nanotech Raises $12.6M Series A to Take a Once-Weekly GLP-1 Patch into Human Trials
The Boston biotech wants to replace the GLP-1 injection with a room-temperature patch — no needles, no cold storage. Its Series A funds the first clinical test of that idea.
media age.house
Anodyne Nanotech, a clinical-stage biotech based in Boston, has closed a $12.6 million Series A to push its lead product — a once-weekly GLP-1 patch for obesity — into Phase I clinical trials, the company announced on June 24, 2026.
The round was led by Velocity Partners VC, co-led by Evercurious VC, with major participation from Relativity Healthcare Partners.
The Technology
GLP-1 drugs have become one of the fastest-growing categories in medicine, but they are almost always delivered by injection and often require cold storage. Anodyne is betting that a patch can remove both frictions.
The company builds solid-state microneedle patches designed to deliver multi-milligram doses of large molecules — peptides, antibodies, and nucleic-acid therapeutics — through the skin, from a patch that is stable at room temperature while aiming to match the efficacy of an injection.
Its lead program, ANN-101, applies that platform to a once-weekly GLP-1 patch for obesity, eliminating both the needle and the need for refrigeration.
“Biologic drugs are still delivered via injections, creating friction for patients and limiting adherence, especially in chronic conditions,” said George Papastergiou, Partner at Velocity Partners VC.
What the Money Funds
The Series A is earmarked for four things:
- Advancing ANN-101 into Phase I clinical trials;
- Accelerating the broader transdermal platform for peptides, monoclonal antibodies, and nucleic-acid therapeutics;
- Supporting manufacturing scale-up; and
- Expanding strategic partnering activity.
“Our lead program, ANN-101, addresses significant unmet needs in a disease rapidly coming to the forefront of healthcare,” said Jake Lombardo, CEO of Anodyne Nanotech.
The Team
Alongside the raise, Vikram Lamba has joined Anodyne’s board of directors. He brings more than 30 years in pharma and biotech leadership, including a prior CEO role at Zosano Pharma and senior M&A positions at Bayer AG.
The round places Anodyne among a wave of companies racing to reshape how GLP-1 therapies reach patients — not the molecules themselves, but the delivery — as the obesity-drug market expands and adherence to injectable regimens becomes a central commercial battleground.
The round at a glance
- Company: Anodyne Nanotech (Boston, MA)
- Round: $12.6 million Series A
- Investors: Velocity Partners VC (lead), Evercurious VC (co-lead), Relativity Healthcare Partners
- Lead product: ANN-101, a once-weekly GLP-1 patch for obesity
- Use of funds: Phase I trials, platform development, manufacturing scale-up, partnering
Details and quotes are drawn from Anodyne Nanotech’s press release dated June 24, 2026. ANN-101 is an investigational product that has not entered clinical trials at the time of the announcement.
Disclaimer
This content is for informational and educational purposes only and is not medical advice. Always consult a qualified healthcare professional before making changes to your health.
